US IP Index Based On 'Flawed' Assumptions, Claim Indian Pharma Firms

Indian drug makers have blasted the US Chamber of Commerce’s Global Innovation Policy Center over its International IP Index, saying its compilation is based on a “flawed” assumption that stronger patents drive greater innovation, and that it ignores individual national concerns.

Indian flag
Debate Rolls On Over Extent Of India's IP Protection

India’s ranking actually improved in absolute and relative terms among the 50 countries in the newest annual International IP Index prepared by the US Chamber of Commerce's Global Innovation Policy Center (GIPC), which analyses the intellectual property (IP) climate around the world. India, long seen as an outlier by big pharma over what it regards as the country’s failure to respect IP rights, broke free of the bottom 10% of nations in the new GIPC Index, moving up to 44th out of 50 countries, from 43rd spot out of 45 nations last year.

But the Indian Pharmaceutical Alliance (IPA), representing 20 of India’s largest domestic drug makers which collectively account for 85% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia